1. Home
  2. BRBI vs SLGL Comparison

BRBI vs SLGL Comparison

Compare BRBI & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BRBI BR Partners S.A. ADSs

BRBI

BRBI BR Partners S.A. ADSs

N/A

Current Price

$9.54

Market Cap

293.2M

Sector

Finance

ML Signal

N/A

Logo Sol-Gel Technologies Ltd.

SLGL

Sol-Gel Technologies Ltd.

SELL

Current Price

$77.73

Market Cap

276.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BRBI
SLGL
Founded
2009
1997
Country
Brazil
Israel
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.2M
276.9M
IPO Year
2025
2016

Fundamental Metrics

Financial Performance
Metric
BRBI
SLGL
Price
$9.54
$77.73
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$110.00
AVG Volume (30 Days)
964.0
41.1K
Earning Date
05-08-2026
05-22-2026
Dividend Yield
5.03%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17.24
$223.84
P/E Ratio
$11.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.09
$20.06
52 Week High
$67.01
$97.97

Technical Indicators

Market Signals
Indicator
BRBI
SLGL
Relative Strength Index (RSI) 35.31 48.57
Support Level N/A $67.89
Resistance Level $15.06 $81.18
Average True Range (ATR) 0.09 6.41
MACD -0.05 -0.77
Stochastic Oscillator 15.62 44.24

Price Performance

Historical Comparison
BRBI
SLGL

About BRBI BRBI BR Partners S.A. ADSs

BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered. However, the company divides it's operations into the following business lines: (1) investment banking and capital markets, (2) treasury sales & structuring, (3) investments and wealth management and (4) capital remuneration.

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.

Share on Social Networks: